Kornimate/medical-research-clean huggingface dataset:
smart identification of ventricular tachycardia isthmus

Conditions: Ventricular Tachycardia; Ischemic Cardiomyopathy

Summary: context : ventricular tachycardia (vt) are serious heart rhythm disorders which can lead to sudden death. a curative treatment for these abnormalities in the cardiac electrical conduction system is possible through an interventional electrophysiology procedure. a catheter is inserted, generally via a femoral access, and is introduced in the heart ventricles in order to collect various 3d electro-anatomical maps. the pace-mapping technique developed in nancy (de chillou et al, heart rhythm 2014) allows the reentrant circuit underlying the vt to be identified, as well as a definition of the target zones to be ablated, using radiofrequency energy with the catheter. the pace-mapping technique consists of stimulating the ventricle from various sites within its internal surface, in order to generate different activation pathways of the myocardium. when an activation pathway is similar to the vt pathway, this means that the stimulation site is located near the pathologic zone to be ablated. the surface electrocardiogram (ecg) is used to compare activation pathways. a 3d correlation ma is then generated: the zones with high correlation (\>90%) indicated the exit of the reentrant circuit, while rapid transition zones (several %/mm) indicate the entrance of the vt circuit. the pace-mapping technique has several limitations: (i) it requires an ecg recording of the clinical vt of the patient (spontaneous or induced at the beginning of the procedure), however it is not always possible to induce it; (ii) sometimes several vt circuits may be present, rendering the procedure of identification and ablation non-exhaustive. the aim of this study is to analyze retrospectively electroanatomical data collected during the intervention, in order to develop a new method for identifying target zones to be ablated, and to compare the results with the conventionally used method. hypothesis : the investigators hypothesize that alternative methods to analyze electroanatomical data (surface ecg and spatial coordinates of the pacing sites) could provide information equivalent to conventional methods (e.g. vt correlation map, vt activation maps etc...) without the need for a reference recording of the clinical vt of the patient.


Eligibility criteria:
inclusion criteria: * ventricular tachycardia ablation between october 2014 and april 2021 * patient for whom electroanatomical data are available. * ischemic cardiomyopathy / previous myocardial infarction * at least 30 points of pace-mapping during the vt procedure exclusion criteria: * incomplete data * poor quality ecg recordings * absence of ventricular tachycardia isthmus identified during the procedure
deployment-related lung disease research database and biorepository

Conditions: Bronchiolitis

Summary: the purpose of this research study is to establish a research database and biorepository for patients at national jewish health (njh) who served in operation iraqi freedom (oif) or operation enduring freedom (oef). this study will also include civilian contractors who worked as part of these military operations in iraq or afghanistan. the biorepository would store blood samples obtained from these patients during a clinic visit. the research database would store prospectively and retrospectively collected clinical and exposure data that would enable us to comprehensively characterize each case.

if informed consent is obtained, test results and other information collected for clinical reasons will be entered in a research database designed and maintained by deohs staff. the clinical data collected are part of the routine diagnosis and care of these patients. no additional procedures are required for the purpose of this research database. collection of symptom and exposure data using a questionnaire designed for this study. all njh patients who served in southwest asia will be approached for inclusion in the study. this will also attempt to contact patients evaluated previously at njh for deployment-related lung disease to obtain informed consent to include data from their medical record and the research questionnaire in the database.

Eligibility criteria:
inclusion criteria: * served in the southwest asia wars exclusion criteria: * did not served in the southwest asia wars
preventive physical activity intervention in head and neck cancer

Conditions: Head and Neck Neoplasms; Physical Inactivity

Summary: the study includes patients with tumors of the oropharynx, larynx and hypopharynx scheduled to receive radiotherapy with curative intent (+/- chemotherapy). the patients will be randomized into either an intervention group (performing a preventive physical activity protocol before and during radiotherapy) or a control group not performing a specified physical exercise protocol. all patients will be in contact with with a speech language pathologist or a physical therapist weekly during radiotherapy. the study is expected to improve physical function and quality of life during and after oncologic treatment


Eligibility criteria:
inclusion criteria: * head and neck cancer (tumors of the oropharynx, pharynx, hypopharynx and larynx) * receiving radiohterapy (+/- chemotherapy) with curative intent exclusion criteria: * surgery due to head and neck cancer * previous treatment for head and neck cancer * tracheostomized patients * inability to perform exercise intervention * inability to perform part of 6-minute walking test * inability to independently fill out questionnaires in swedish * previous neurologic or neuromuscular disease
proof of principle for a diagnostic blood test of recurrent seizures

Conditions: Epilepsy

Summary: the primary goal of this observational study is to establish the accuracy of cns-specific assay for recurrent paroxysmal events (carpe) as a diagnostic blood test for epilepsy. the target population is patients who have been newly referred to the penn epilepsy center or patients who are admitted to hup for continuous video eeg monitoring. (subjects without an epilepsy diagnosis will be included.) subjects will be asked to provide consent, agree to allow the study team to collect information from their medical record, and to provide at least one blood sample.


Eligibility criteria:
inclusion criteria: * male/female patients aged 12 and older * evaluation in at least one of the following settings: * newly referred to the university of pennsylvania penn epilepsy center. these patients may not have completed any diagnostic evaluation at penn, other than an initial physician consultation, prior to enrollment and must agree to allow the study team to collect records regarding their diagnostic evaluations (including eeg). diagnostic evaluations may take place at penn or outside sites * all patients who are admitted to the university of pennsylvania for continuous video eeg (cveeg) monitoring exclusion criteria: * patients who, in the opinion of the investigator or the patients neurologist, are unable to give informed consent due to mental impairment or any other reason and do not have a lar who can give informed consent on their behalf. patients aged 12-17 (inclusive) must provide assent if they are mentally capable of doing so, and must also have a caregiver who provides informed consent on their behalf * patients who, in the opinion of their neurologist at the university of pennsylvania, are not good candidates for donating blood for any reason

Keywords: epilepsy seizures diagnosis diagnostic inflammation
effect of intraperitoneal nebulisation of magnesium sulphate for analgesia following laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: intraperitoneal nebulisation with magnesuim sulphate will reduce post operative pain and analgesic consumption in postoperative period following laparoscopic cholecystectomy.

sixty patients undergoing laparoscopic cholecystectomy belonging to american society of anaesthesiologist (i-ii) of age 18-65 yrs will be enrolled.group one (n=30) will receive 1.5 gm magnesium sulphate diluted in 3ml of normal saline and group 2 (n=30) will receive 5 ml of ns.

Eligibility criteria:
inclusion criteria: asa i-ii - exclusion criteria: history of -

Keywords: magnesium sulpahate postoperative analgesia
an observational pilot study evaluating the feasibility of conducting genome-wide association studies utilizing subject provided information in subjects with locally recurrent or mbc, mcrc, mnsclc, rgbm or mrcc treated with avastin (bevacizumab) (invite)

Conditions: Breast Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Cancer

Summary: this pilot, non-interventional, observational, web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (bc) or metastatic breast cancer (mbc), metastatic colorectal cancer (mcrc), metastatic non-squamous non-small cell lung cancer (mnsclc), recurrent glioblastoma (rgbm), or metastatic renal cell cancer (mrcc) in the united states who have been previously treated with avastin (bevacizumab). the cohort will be composed of male and female subjects who have been diagnosed with locally recurrent bc or mbc, mcrc, mnsclc, rgbm, or mrcc who have received treatment with bevacizumab in combination with chemotherapy, which started prior to or up to 31 december 2012. participants will be self-referred to this study. they will be recruited online via a number of sources, including through the involvement of patient advocacy groups, social media tools, traditional media, physicians, and events to raise awareness of this study. after appropriate informed consent and authorization are obtained, data will be collected directly from subjects in an online survey. participants will be contacted electronically to complete quarterly follow-up surveys. the follow-up period will be 1 year from responding to the baseline survey. dna collection will be performed as part of this study. dna will be extracted from saliva, which will be provided by the subject utilizing a collection kit sent to the participants for at-home use.


Eligibility criteria:
inclusion criteria: * locally recurrent bc or mbc, mcrc, mnsclc, rgbm, or mrcc in patients treated or on treatment with bevacizumab, which started prior to or up to 31 december 2012 * ability to read and understand english * ability to access and use a computer connected to the internet * signed informed consent and authorization form * residence in the united states * at least 18 years of age exclusion criteria: n/a
influence of anesthesia technique on postoperative evolution after urogenital surgical interventions

Conditions: Anesthesia; Reaction; Adverse Effect of Other General Anesthetics; Adverse Anesthesia Outcome; Acute Kidney Injury

Summary: the study hypothesis is that regional anesthesia offers better outcome for the patients who underwent robot assisted laparoscopic urogenital surgery.

the study investigates the effect of combined anesthesia on occurrence of acute kidney injury in robot assisted laparoscopic urogenital surgery.renal function is assessed according to the new rifle and akin criteria, and by determining serum and urinary neutrophil gelatinase associated lipocalin.

Eligibility criteria:
inclusion criteria: * signed the informed consent without previous renal function alteration respiratory and hemodynamic stability exclusion criteria: * refuse to sign the informed consent chronic or and stage renal disease severe systemic diseases
¡si, yo puedo control mi diabetes!: a diabetes self-management education program for hispanic/latinos

Conditions: Type 2 Diabetes, Hispanic/Latinos, Diabetes Self-management Education

Summary: the purpose of the study is to evaluate the effectiveness of the ísi, yo puedo controlar mi diabetes! (yo puedo) diabetes self-management education program.


Eligibility criteria:
inclusion criteria: self-identification as hispanic/latino, over the age of 18 years of age, diagnosis of type 2 diabetes and willingness to participate in the diabetes self-management education class. exclusion criteria: non-diabetic persons, non english-speaking hispanic/latinos with type 2 diabetes -
adrenal venous sampling in patients with overt or subclinical cushings syndrome, and bilateral adrenal tumors

Conditions: Cushing Syndrome

Summary: patients with tumors in both adrenal glands and slightly elevated cortisol (subclinical cushings syndrome) are offered to go through an adrenal venous sampling to try to quantify if the overproduction of cortisol is from one adrenal, or from both sides. if it is one-sided, the investigators offer the patient operation.

adrenal incidentalomas are quite common. about 4 % of the population have adrenal tumors that they are unknown of. some percentage of this patients produce a little to much cortisol, but not enough to give overt cushings syndrome. it is shown that slightly elevated cortisol production will give higher blood pressure, higher blood sugar and maybe higher bmi. for another hormone produced in the adrenal glands , aldosterone, we know that even if you have an adrenal tumor on one adrenal, you could have bilateral overproduction of the hormone.in that situations it is no need of an operation of the adrenal with the tumor. when the overproduction is unilateral it is of great value to the patient to operate the adrenal gland, and the symptoms from the hormone excess will disappear. for aldosterone adrenal venous sampling (avs) has been used for several years to try to determine if the hormone overproduction is one-sided or to sided. we are in this study using the same principle for cortisol overproduction.

Eligibility criteria:
inclusion criteria: * benign tumors/adenomas in the adrenals and biochemically overproduction of cortisol exclusion criteria: * use of steroids ( tablets, inhalations, lotions)
intravenous paracetamol compared dexketoprofen for postoperative analgesia after septoplasty

Conditions: Postoperative Pain

Summary: the investigators conducted a prospective, randomized, double blind study to compare the effectiveness of intravenous paracetamol and dexketoprofen for preventing pain during first 24 hours postoperative period in adult patient undergoing septoplasty.

postoperative pain scores as measured by visual analog scale (vas) (0 represented no pain and 10 the worst pain ever experienced) at 15, 30, 60 minutes and 2th, 4th, 6th, 12th and 24th hours postoperatively.

Eligibility criteria:
inclusion criteria: * after patient's inform consent was approved, a total of 70 asa (american society of anesthesiology) physical status i and ii adult patients age 18 to 65 undergoing septoplasty were planned include the study. exclusion criteria: * history of clotting disorders or blood dyscrasias, * gastrointestinal ulcer or chronic dyspepsia, * history of allergy to the study drugs, * active bleeding or bleeding disorders.

Keywords: paracetamol dexketoprofen postoperative pain septoplasty
dose escalation study of nkp-1339 to treat advanced solid tumors

Conditions: Solid Tumors

Summary: the purpose of this study is to determine the safety and maximal tolerated dose of nkp-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors. the responses to treatment in this population will be evaluated. in addition, the pd and pk properties of the compound will be explored.

nkp-1339 is a novel grp78 targeted ruthenium based anti-cancer compound which is intravenously administered. grp78 is a key regulator of misfolded protein processing, which is unregulated in cancer cells. in nonclinical anti-tumor studies, nkp-1339 showed activity against many tumor types, including those resistant to platinum and other standard anti-cancer agents. this phase i trial evaluates the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of nkp-1339.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years with histologically or cytologically confirmed advanced solid tumors refractory to standard therapies who have signed an irb approved informed consent form (icf). * ecog ps 0 or 1. * adequate hematologic, hepatic and renal function * minimum life expectancy ≥ 12 weeks exclusion criteria: * no supplemental iron, i.e., therapeutic or as part of a multivitamin regimen. * no chemotherapy, immunotherapy, or radiotherapy for \< 4 weeks, bmts \< 9 months or major surgery \< 3 weeks. * no symptomatic central nervous system metastases. no primary brain tumors or known brain metastasis unless clinically stable and on stable or reducing dose of steroids. * no evidence of ischemia, mi within the past 6 months, or other significant abnormality on ecg. * no clinically significant active infection including hiv, hepatitis b, or hepatitis c. * no peripheral neuropathy ≥ grade 2

Keywords: phase 1 advanced solid tumors
calcium-protein co-ingestion and gut hormones

Conditions: Obesity; Diabetes

Summary: gut hormones have therapeutic potential in the prevention and treatment obesity and type 2 diabetes (t2d). rodent evidence suggests that calcium may potentiate the effects of protein ingestion on gut hormone secretion. evidence in humans however, is lacking. this study aims to assess whether the addition of calcium to protein ingestion augments postprandial gut hormone availability in humans.


Eligibility criteria:
inclusion criteria: * healthy men and women age between 18-65 yrs. * able to consume provided supplement. * weight stable for the past 3 month (no change within 3%) exclusion criteria: * any previous or current metabolic, cardio-pulmonary or musculoskeletal disease * not between the ages of 18-65 years * a body mass index below 18.5 kg/m2 or above 30 kg/m2 (body mass (kg) divided by your height (m) squared) * taking medications that may influence your metabolism * plans to change your lifestyle (diet and/or physical activity) during the study period * not willing to refrain from alcohol containing drinks or unaccustomed exercise one day before the laboratory sessions. * current smoker
colorectal cancer rechallenge

Conditions: Colorectal Neoplasms

Summary: primary objective: * to demonstrate that re-challenge with an oxaliplatin based regimen (modified folfox-6) will provide a clinical disease control rate (dcr) of at least 20% at the end of the chemotherapy. secondary objective: * to evaluate other measures of tumour's responses and safety.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of colon or rectum * measurable metastatic disease, either inoperable, or residual after surgical procedure * no prior chemotherapy for metastatic disease * for colon cancer: prior adjuvant chemotherapy with oxaliplatin that ended at least 12 months prior to enrollment. * for rectal cancer: at least 12 months since prior use of oxaliplatin in neoadjuvant or adjuvant chemotherapy * adequate liver and kidney function: * total bilirubin inferior to 1.5 uln * serum creatinine inferior to 150 umol/l * creatinine clearance (clcr) \> 30 ml/min * alt / ast inferior to 3 uln * adequate hematological function * neutrophils \> or equal 1.5 x 109/l * platelets \> or equal 100 x 109/l exclusion criteria: * metastatic disease presenting without prior adjuvant chemotherapy * metastatic disease presenting after non-oxaliplatin-containing adjuvant chemotherapy * peripheral sensory or motor neuropathy \> grade 1 * eastern cooperative oncology group (ecog) performance status \> 2 * other active malignancy * history of known allergy to oxaliplatin or other platinum compounds, to 5-fu, to leucovorin or to any ingredients in the formulations or the containers * patients who are pregnant, or breast-feeding * patients with severe renal impairment (clcr \< 30 ml/min) * pernicious anemia or other megaloblastic anemia with vitamin b12 deficiency * patients with reproductive potential not implementing accepted and effective method of contraception (the definition of effective method of contraception will be based on the investigators' judgment) * participation in another clinical trial with any investigational drug within 30 days prior to study screening * for patient who will receive bevacizumab: bevacizumab is contraindicated in patients with know hypersensitivity to any components of the product and to chinese hamster ovary cell product or other recombinant human or humanized antibodies * presence of any symptoms suggesting brain metastasis the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
an extension study of ublituximab in participants with relapsing multiple sclerosis

Conditions: Relapsing Multiple Sclerosis (RMS)

Summary: the purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (rms).

tg1101-rms303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with rms. participants who complete the 96-week, double-blind treatment period of tg1101-rms301 (rms301 \[nct03277261\]) or tg1101-rms302 (rms302 \[nct03277248\]) are eligible for participation in this open label extension (ole) study. participants may also be eligible for tg1101-rms303 if they have completed week 208 of tg1101-rms201e (rms201e \[nct03381170\]) (united states of america \[usa\] participants only).

Eligibility criteria:
inclusion criteria: participants must meet the following criteria: 1. complete the 96-week double-blind tg1101-rms301 (nct03277261) or tg1101-rms302 (nct03277248) study or complete the final week 208 visit of the tg1101-rms201e (nct03381170) study 2. investigator believes may benefit from treatment with ublituximab 3. are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol 4. female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab exclusion criteria: participants who meet any of the following exclusion criteria are not to be enrolled to this study: 1. any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as: 1. absolute neutrophil count \< 1.5 x 10e3/µl 2. hematocrit \< 24% 3. platelet count \< 150,000 cell/mm\^3 4. hypogammaglobulinemia immunoglobulin g (igg) \< 4.0g/l 2. active infection 3. ongoing pregnancy (female participants) 4. participants who discontinued ublituximab treatment or withdrew consent from the tg1101-rms301 or tg1101-rms302 study during the 96-week evaluation period or prior to completing the final week 208 visit of the tg1101-rms201e study 5. participants who have started any disease modifying therapy (dmt), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the tg1101-rms301, tg1101-rms302, or after completing the final week 208 visit of the tg1101-rms201e study 6. participants who have had a confirmed multiple sclerosis (ms) relapse within the past 30 days prior to week 1 day 1 (w1d1). following a relapse, participants must be neurologically stable for at least 30 days prior to screening or w1d1 of the ole 7. participants with unstable disease activity 8. presence of malignancy, except for surgically excised basal or squamous cell skin lesions 9. vaccination with live virus within 2 months of randomization